drug_type
RELEVANT_DRUG
intervention_type
Biologic immunotherapy (monoclonal antibody)
drug_description
Humanized, afucosylated IgG1 monoclonal antibody targeting IL-5 receptor alpha (IL-5Rα); blocks IL-5 signaling and induces ADCC-mediated depletion of eosinophils to control severe eosinophilic asthma.
nci_thesaurus_concept_id
C88594
nci_thesaurus_preferred_term
Benralizumab
nci_thesaurus_definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated humanized IgG1 monoclonal antibody targeting IL-5 receptor alpha on eosinophils and basophils; blocks IL-5 signaling and, via enhanced FcγRIIIa engagement, induces strong NK cell–mediated ADCC to deplete eosinophils, thereby reducing eosinophilic inflammation and asthma exacerbations.
drug_name
Benralizumab
nct_id_drug_ref
NCT06465485